Last reviewed · How we verify

ATI-5923 — Competitive Intelligence Brief

ATI-5923 (ATI-5923) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 9 (PDE9) inhibitor. Area: Neurology.

phase 2 Phosphodiesterase 9 (PDE9) inhibitor PDE9 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ATI-5923 (ATI-5923) — ARYx Therapeutics. ATI-5923 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ATI-5923 TARGET ATI-5923 ARYx Therapeutics phase 2 Phosphodiesterase 9 (PDE9) inhibitor PDE9
NI-071 NI-071 Nichi-Iko Pharmaceutical Co., Ltd. phase 3 Phosphodiesterase 9 (PDE9) inhibitor PDE9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 9 (PDE9) inhibitor class)

  1. ARYx Therapeutics · 1 drug in this class
  2. Nichi-Iko Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATI-5923 — Competitive Intelligence Brief. https://druglandscape.com/ci/ati-5923. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: